HDAC inhibitor-based therapies: can we interpret the code?
Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...
المؤلفون الرئيسيون: | New, M, Olzscha, H, La Thangue, N |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2012
|
مواد مشابهة
-
The TLR adaptor protein MyD88 mediates cell sensitivity to HDAC inhibitors through a cytokine-dependent mechanism
حسب: Sheikh, S, وآخرون
منشور في: (2016) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
حسب: New, M, وآخرون
منشور في: (2013) -
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
حسب: New, M, وآخرون
منشور في: (2013) -
HDAC inhibitor-based therapies and haematological malignancy.
حسب: Stimson, L, وآخرون
منشور في: (2009) -
TLR adaptor protein MYD88 mediates sensitivity to HDAC inhibitors via a cytokine-dependent mechanism
حسب: New, M, وآخرون
منشور في: (2016)